SCHEDULE 13G/A: Orca Capital AG Discloses 4.1% Stake in Can-Fite BioPharma Following Recent Offering
Beneficial Ownership Report
Orca Capital AG has filed an amended Schedule 13G, reporting a 4.1% beneficial ownership stake in Can-Fite BioPharma Ltd., calculated after the issuer's recent registered offering.
Summary
- Orca Capital AG reported beneficial ownership of 157,382,700 Ordinary Shares of Can-Fite BioPharma Ltd.
- This stake represents 4.1% of the issuer's outstanding Ordinary Shares.
- The ownership percentage is calculated based on an aggregate of 3,855,926,493 Ordinary Shares outstanding.
- This total includes shares issued immediately after giving effect to the completion of Can-Fite BioPharma's registered offering, as described in a Prospectus Supplement filed on April 15, 2025.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
- Orca Capital AG, a German entity, holds sole voting and dispositive power over these shares.
- The securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard SEC Schedule 13G filing, reporting a factual beneficial ownership stake. It does not contain performance indicators, forward-looking statements, or qualitative assessments that would significantly influence sentiment beyond a neutral reporting of compliance.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which may influence perceptions of institutional interest in the company.
- Investors: Offers updated information on the ownership structure, particularly after a recent share offering, which can be relevant for market analysis.
Key Dates
| Date | Description |
|---|---|
| 04/15/2025 | Date of filing of Can-Fite BioPharma Ltd.'s Prospectus Supplement for its registered offering. |
| 04/22/2025 | Date of event which required the filing of this Schedule 13G statement by Orca Capital AG. |
| 04/23/2025 | Date of signature for the Schedule 13G filing by Orca Capital AG. |
Keywords
Can-Fite BioPharma Ltd., Orca Capital AG, Schedule 13G, Beneficial Ownership, Ordinary Shares, SEC Filing, Biopharma, Investment, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.